DE SOCIO, GIUSEPPE VITTORIO LUIGI
 Distribuzione geografica
Continente #
AS - Asia 2.034
NA - Nord America 1.744
EU - Europa 1.154
SA - Sud America 861
AF - Africa 54
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.848
Nazione #
US - Stati Uniti d'America 1.667
SG - Singapore 744
BR - Brasile 690
VN - Vietnam 407
CN - Cina 288
IT - Italia 215
HK - Hong Kong 214
KR - Corea 196
IE - Irlanda 194
SE - Svezia 140
DE - Germania 132
UA - Ucraina 118
RU - Federazione Russa 105
GB - Regno Unito 66
FI - Finlandia 64
AR - Argentina 62
EC - Ecuador 42
MX - Messico 37
FR - Francia 36
ID - Indonesia 33
TR - Turchia 33
CA - Canada 32
AT - Austria 25
BD - Bangladesh 24
IN - India 24
CO - Colombia 18
PL - Polonia 16
JP - Giappone 14
ZA - Sudafrica 14
PE - Perù 11
VE - Venezuela 11
PY - Paraguay 10
IQ - Iraq 9
MA - Marocco 9
NL - Olanda 9
CL - Cile 8
EG - Egitto 8
ES - Italia 8
UZ - Uzbekistan 8
LB - Libano 7
AE - Emirati Arabi Uniti 6
KE - Kenya 5
LT - Lituania 5
BE - Belgio 4
BO - Bolivia 4
GR - Grecia 4
JO - Giordania 4
PK - Pakistan 4
UY - Uruguay 4
CH - Svizzera 3
CR - Costa Rica 3
DZ - Algeria 3
KW - Kuwait 3
KZ - Kazakistan 3
SD - Sudan 3
SN - Senegal 3
TN - Tunisia 3
AL - Albania 2
AZ - Azerbaigian 2
BH - Bahrain 2
CZ - Repubblica Ceca 2
NO - Norvegia 2
NP - Nepal 2
TH - Thailandia 2
BG - Bulgaria 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GN - Guinea 1
GT - Guatemala 1
GY - Guiana 1
HT - Haiti 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
LV - Lettonia 1
MG - Madagascar 1
MK - Macedonia 1
ML - Mali 1
NA - Namibia 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
PR - Porto Rico 1
SA - Arabia Saudita 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.848
Città #
Singapore 462
Hong Kong 213
Seoul 195
Chandler 193
Dublin 191
Ho Chi Minh City 138
Ashburn 102
Columbus 100
Piscataway 92
San Mateo 86
Hanoi 70
Dong Ket 67
São Paulo 65
Boardman 62
Santa Clara 61
Jacksonville 58
Munich 55
Altamura 54
New York 54
Beijing 51
Perugia 51
Medford 45
Princeton 45
Los Angeles 43
Lawrence 38
Wilmington 38
Ann Arbor 33
Rio de Janeiro 32
Hefei 30
Moscow 30
Des Moines 24
Helsinki 24
Mexico City 22
Falls Church 20
Haiphong 19
The Dalles 19
Dallas 18
Nuremberg 18
Andover 17
Denver 15
Turku 15
Guayaquil 14
Tokyo 14
Montreal 13
Warsaw 13
Curitiba 12
Padova 12
Poplar 12
Porto Alegre 12
Vienna 12
Brooklyn 11
Guangzhou 11
Guarulhos 11
Houston 11
Milan 11
Quito 11
Rome 11
Chennai 10
Florence 10
Ninh Bình 10
Salvador 10
Woodbridge 10
Ankara 9
Boston 9
Brasília 9
Campinas 9
Frankfurt am Main 9
London 9
Mersin 9
Norwalk 9
Orem 9
Stockholm 9
Amsterdam 8
Belo Horizonte 8
Biên Hòa 8
Bologna 8
Izmir 8
Johannesburg 8
Manaus 8
Redmond 8
Thái Bình 8
Toronto 8
Atlanta 7
Da Nang 7
Fortaleza 7
Düsseldorf 6
Falkenstein 6
Hải Dương 6
Jakarta 6
Phoenix 6
Recife 6
Ribeirão Preto 6
Shanghai 6
Sorocaba 6
Bevagna 5
Bắc Giang 5
Carapicuíba 5
Catania 5
Hortolândia 5
Lima 5
Totale 3.481
Nome #
Aortic stiffness in untreated adult patients with human immunodeficiency virus infection. 124
Predictive value of National Early Warning Score 2 (NEWS2) for intensive care unit admission in patients with SARS-CoV-2 infection 122
Accelerate Pheno™ system in sepsis by Gram-negative pathogens: four months of hospital experience 117
Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection. 116
Acute cytomegalovirus meningomyelitis in an immunocompetent patient. 113
Achromobacter denitrificans renal abscess. 106
Accelerate Pheno™ blood culture detection system: a literature review 106
Impact of treatment with protease inhibitors on aortic stiffness in adult patients with human immunodeficiency virus infection. 97
Measurement and prediction of antimicrobial resistance in bloodstream infections by ESKAPE pathogens and Escherichia coli 95
Partial achievement of the 90-90-90 UNAIDS target in a cohort of HIV infected patients from Central Italy 95
Hepatitis C virus genotypes in the liver and serum of patients with chronic hepatitis C 83
Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia A Randomized Clinical Trial 83
Accuracy and impact on patient management of new tools for diagnosis of sepsis: Experience with the t2 magnetic resonance bacteria panel 83
Semiquantitative PCR in the diagnosis of HIV infection: correlation to clinical stage and serological status. 82
Smoking Habits in Human Immunodeficiency Virus-Infected People from Italy: A Cross-Sectional Analysis of the STOPSHIV Cohort 82
Delivery in asymptomatic Italian woman with SARS-CoV-2 infection 80
Evaluation of IVD 3.0 Vitek MS matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of Mycobacterium tuberculosis and nontuberculous mycobacteria and its use in routine diagnostics. 78
Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria 77
[Loa loa filariasis in Italy: review of the literature with a clinical report] 77
National Early Warning Score 2 (NEWS2) better predicts critical Coronavirus Disease 2019 (COVID-19) illness than COVID-GRAM, a multi-centre study 76
Clusterization of co-morbidities and multi-morbidities among persons living with HIV: A cross-sectional study 75
XVI Convegno Nazionale AIDS e SINDROMI CORRELATE 74
Infezioni da Cytomegalovirus nel paziente immunodepresso. 74
Early treatment with bamlanivimab alone does not prevent COVID-19 hospitalization and its post-acute sequelae. A real experience in Umbria, Italy 74
Decreasing cardiovascular risk in HIV infection between 2005 and 2011. 72
Prevalence of smoking and nicotine dependence in HIV patients, the project STOPS HIV from Italy 71
Smoking habits in HIV-infected people compared with the general population in Italy: A cross-sectional study 71
Lingual tubercolosis: a rare disease in western countries 70
Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients 67
Negative influence of HIV infection on day-night blood pressure variability. 66
Le infezioni da Cytomegalovirus ed il loro trattamento nel paziente immunodepresso (AIDS e TMO). 66
Is it feasible to impact on smoking habits in HIV-Infected patients? Mission impossible from the STOPSHIV Project cohort 66
An unusual case of epigastric and back pain: expanding descending thoracic aneurysm resulting from tertiary syphilis diagnosed with positron emission tomography. 64
Laboratory automation reduces time to report of positive blood cultures and improves management of patients with bloodstream infection 62
Bictegravir/Tenofovir Alafenamide/Emtricitabine: A Real-Life Experience in People Living with HIV (PLWH) 59
Improving the etiological diagnosis of osteoarticular infections with the commercial multiplex real-time polymerase chain reaction SeptiFast® 55
Fusobacterium nucleatum endocarditis mimicking polymyalgia rheumatica 53
Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study 53
Observed versus predicted cardiovascular events and all-cause death in HIV infection: A longitudinal cohort study 52
HIV infection and antiretroviral treatment: a "two-hit" model for arterial stiffness? 51
AmBisome administration for Candida albicans shunt infections 50
Dolutegravir/Lamivudine versus Tenofovir Alafenamide/Emtricitabine/Bictegravir as a Switch Strategy in a Real-Life Cohort of Virogically Suppressed People Living with HIV 50
Retroperitoneal abscess: an uncommon localization of tubercular infection. 48
Giant Infective Endocarditis of Native Aortic Valve with Secondary Mitral Kissing Vegetation 47
Thrombocytopenia in HIV infected patients: prevalence and clinical spectrum 46
Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade 45
Antiretroviral therapy and adverse skeletal effects 43
Real-life monocentric Biktarvy cohort from Perugia 42
Laboratory automation, informatics, and artificial intelligence: current and future perspectives in clinical microbiology 42
Symmetric ambulatory arterial stiffness index and 24-h pulse pressure in HIV infection: results of a nationwide cross-sectional study 41
Liver enzyme variation after switching to emtricitabine/tenofovir alafenamide/bictegravir is associated with glucose increase in a real-life cohort 40
Ageing with HIV: a multidisciplinary review 40
Impact of smoking habits on cardiovascular and neoplastic events and all-cause death in people living with HIVfrom the STOPSHIV cohort 40
Effectiveness, safety and tolerability of dolutegravir/lamivudine versus tenofovir alafenamide/emtricitabine/bictegravir in a real-life cohort of HIV-1 virologically suppressed treatment experienced people living with HIV 40
Prevalence, awareness, treatment, and control rate of hypertension in HIV-infected patients: the HIV-HY study. 39
[Renal toxicity in HIV-infected patients receiving HAART including tenofovir] 39
Lack of HIV seroconversion in a patient treated immediately with antiretroviral therapy at acute infection and virus relapse 38
Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study 37
Hypophosphatemic Osteomalacia Associated with Tenofovir: a Multidisciplinary Approach is Required 36
HIV Infection - Screening, Diagnosis, and Treatment 36
A study of SARS-CoV-2 epidemiology in Italy: from early days to secondary effects after social distancing 35
[Low incidence of streptococcal pharyngitis in young adults] 35
Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and Hypertension Study 35
Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-Infected Patients 33
A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks' observational data 33
96 Week follow-up of HIV-infected patients in rescue with raltegravir plus optimized backbone regimens: a multicentre Italian experience 33
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project 31
Polypharmacy, anticholinergic burden and drug-drug interaction assessment in people with four-class-resistant HIV: data from the PRESTIGIO registry 31
Use of a molecular syndromic panel for the etiological diagnosis of ventilator-associated bacterial pneumonia: impact on clinical outcomes and antibiotic use from a multicenter, prospective study 30
Knowledge of STIs and HIV among people with and without HIV: where are we now? 30
Factors Associated With Weight Gain in People Treated With Dolutegravir 29
[Nosocomial infections in a general surgical ward] 29
Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study 29
Adefovir induced hypophosphatemic osteomalacia 29
Time trend in hypertension prevalence, awareness, treatment, and control in a contemporary cohort of HIV-infected patients: the HIV and Hypertension Study 29
Waist circumference and body mass index in HIV infection 29
Knowledge of Sexually Transmitted Infections and HIV among People Living with HIV: Should We Be Concerned? 28
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry 28
Il fumo di sigaretta, un fattore di rischio maggiore per la popolazione HIV-positiva: strategie di intervento 28
Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project 28
With or without TAF? What is the difference? Data from a real-life setting 28
Efficacy and Tollerability of INI-Based 2-Drug Regimen in Virosuppressed Persons Living with HIV: A Systematic Review and Meta-Analysis 28
Dolutegravir plus ritonavir-boosted darunavir in highly cART-experienced subjects: an observational cohort 28
The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 - 74 years and more than 75 years 27
Is metabolic syndrome associated to HIV infection per se? Results from the HERMES study 27
The use of nucleoside reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients 27
Schizophrenia, drug therapy, and monitoring 27
Alexithymia Predicts Carotid Atherosclerosis, Vascular Events, and All-Cause Mortality in Human Immunodeficiency Virus-Infected Patients: An Italian Multisite Prospective Cohort Study 27
Safety and efficacy of switching people with HIV to dual treatment with 3TC/DTG and RPV/DTG in real life: results from the SCOLTA cohort 26
Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study (vol 72, pg 2879, 2017) 26
Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort 26
Metabolic syndrome: a real threat for HIV-positive patients?: Results from the SIMONE study 26
Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians 26
Two-drug regimens with dolutegravir for maintaining viral suppression: looking at the right companion 25
Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project 25
People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they? 25
Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects 25
Does simplification to dolutegravir-based dual regimens impact on the CD4+/CD8+ T-cell ratio? 24
Screening for Latent Tuberculosis Infection in People Living with HIV: TUBHIVIT Project, a Multicenter Italian Study 24
Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA) 24
Totale 5.159
Categoria #
all - tutte 27.509
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.509


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021227 0 0 0 0 0 32 18 15 45 16 27 74
2021/2022362 9 58 10 25 18 15 7 91 13 13 47 56
2022/2023678 48 130 11 54 44 83 9 23 246 0 16 14
2023/2024272 11 33 14 5 4 1 71 3 23 11 51 45
2024/20251.323 9 68 24 29 77 48 54 55 216 277 201 265
2025/20262.898 309 386 451 1.176 424 152 0 0 0 0 0 0
Totale 6.131